A solvent free method of concentrating naturally occurring 2 - carboxylic acid cannabinoids contained in fresh Cannabis: THCA (Tetrahydrocannabinolic acid), CBDA (Cannabidiolic acid), CBNA (Cannabinol acid), CBGa (Cannabigerol acid), CBCA (Cannabichromene acid), CBLA (Cannabicyclol acid), CBVA (Cannabivarin acid), THCVA (Tetrahydrocannabivarin acid), CBDVA (Cannabidivarin acid), CBCVA (Cannabichromevarin acid), CBGVA (Cannabigerovarin acid), CBGM (Cannabigerol Monomethyl Ether acid), CBE (Cannabielsoin acid) and CBT (Cannabicitran acid) by lyophilization to limit decarboxylation of these plant acids catalyzed by heat, light or alkaline conditions and to concentrate cannabinolic acids for cold milling to powder for encapsulation or to enhance extraction and purification of CBDA and THCA. When combined with a preponderance of CBDA, cannabinolic acids offer a safer, more effective alternative than non-steroid anti-inflammatory drugs (NSAID's) or NSAID-Opioid combinations for alleviation of pain, inflammation and to provide neuroprotection. Chronic NSAID use is known to produce adverse effects on heart, liver, kidney and blood. Chronic NSAID-Opioid use is associated with adverse effects on heart, liver, kidney, blood and opioid addiction. The combination of CBDA and THCA is 100 times more effective than NSAID's like Ibuprofen for relief of pain, reduction of inflammation and to provide neuroprotection with no known adverse effects.L'invention concerne un procédé sans solvant de concentration de cannabinoïdes d'acide 2-carboxylique d'origine naturelle contenus dans du cannabis frais : THCA (acide tétrahydrocannabinolique), CBDA (acide cannabidiolique), CBNA (acide cannabinol), CBGa (acide cannabigérol), CBCA (acide cannabichromique), CBLA (acide cannabicyclol), CBVA (acide cannabivarine), THCVA (acide tétrahydrocannabivarine), CBDVA (acide cannabidivarine), CBCVA (acide cannabichromévarine), CBGVA (acide cannabigérovarine), CBGM (acide éther monométhylique de cannabigéro
